NEW YORK and WALTHAM, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...
GAMMAGARD LIQUID [immune globulin infusion (human)] 10% solution by Baxter Baxter announced that the FDA has approved Gammagard Liquid 10% (immune globulin infusion [human]) for the treatment of ...
"Multifocal Motor Neuropathy Pipeline Insight"DelveInsight's analysis reveals several companies advancing innovative therapies in the multifocal motor neuropathy clinical pipeline, with groundbreaking ...
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
Baxter International announced that it has submitted a supplemental Biologics License Application (sBLA) for Gammagard Liquid 10% [immune globulin infusion (human)] for the treatment of multifocal ...
> Baxter International ($BAX) gained FDA approval to use its Gammagard Liquid 10% (immune globulin infusion) as a treatment for multifocal motor neuropathy, the first ...
Baxter International Inc. (NYSE:BAX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) in 1Q’24 and planned initiation of a Phase 2 trial in Chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results